To date, Leqembi has been approved in the US, Japan, China, South Korea, Hong Kong, Israel, UAE, GB, Mexico, and Macau, and ...

Bristol Myers Squibb CEO Chris Boerner described Cobenefy, a new drug to treat schizophrenia and may also help with bipolar ...

The FDA approved a wide range of therapies in 2024, including many new molecular entities and biological products.

People in the United States are living longer and with that comes increased rates of dementia. Dr. Josef Coresh, with NYU ...

Shares of Intra-Cellular Therapies Inc. (NASDAQ: ITCI) are trading higher Monday after Johnson & Johnson agreed to acquire the company.

The Phase Ia trial is designed to assess the safety and efficacy of the company’s drug designed to target chemicals thought ...

Today's pharmaceutical market is facing the challenges of inflation, government-imposed drug price caps and waning demand for COVID-19 vaccines. However, the industry's major underlying drivers — ...

Intra-Cellular has had success selling Caplyta, a brain-rebalancing drug that's approved to treat schizophrenia and bipolar ...

Johnson & Johnson will spend more than $14 billion to move deeper into treating central nervous system disorders by ...

Alnylam Pharmaceuticals ALNY announced preliminary net product revenues for the fourth quarter and full-year 2024 for its ...